Crinetics Pharmaceuticals, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Checking your notes…

(in thousands)

	Common StockShares	Common Stock and Paid-InCapital	AccumulatedOtherComprehensiveIncome (loss)	AccumulatedDeficit	Stock Held inTrust	TotalStockholders’Equity
Balance at January 1, 2026	95,575	$2,407,757	$1,865	$(1,417,427)	$(112)	$992,083
Exercise of stock options	396	9,942	—	—	—	9,942
Issuance of common stock, net of transaction costs	8,763	379,771	—	—	—	379,771
Issuance of common stock upon vesting of RSUs	580	—	—	—	—	—
Stock-based compensation	—	29,814	—	—	—	29,814
Stock held in trust under deferred compensation plan	—	920	—	—	(920)	—
Other comprehensive loss	—	—	(3,119)	—	—	(3,119)
Net loss	—	—	—	(127,845)	—	(127,845)
Balance at March 31, 2026	105,314	$2,828,204	$(1,254)	$(1,545,272)	$(1,032)	$1,280,646
Balance on January 1, 2025	92,926	$2,275,952	$963	$(952,110)	$—	$1,324,805
Exercise of stock options	215	4,452	—	—	—	4,452
Issuance of common stock upon vesting of RSUs	384	—	—	—	—	—
Stock-based compensation	—	20,478	—	—	—	20,478
Other comprehensive income	—	—	1,039	—	—	1,039
Net loss	—	—	—	(96,774)	—	(96,774)
Balance at March 31, 2025	93,525	$2,300,882	$2,002	$(1,048,884)	$—	$1,254,000

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.